Home Cart 0 Sign in  
X

[ CAS No. 1035219-96-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 1035219-96-5
Chemical Structure| 1035219-96-5
Chemical Structure| 1035219-96-5
Structure of 1035219-96-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1035219-96-5 ]

Related Doc. of [ 1035219-96-5 ]

Alternatived Products of [ 1035219-96-5 ]

Product Details of [ 1035219-96-5 ]

CAS No. :1035219-96-5 MDL No. :MFCD14706758
Formula : C6H5BrN2OS Boiling Point : -
Linear Structure Formula :- InChI Key :FUSXFJPOPDRDHZ-UHFFFAOYSA-N
M.W : 233.09 Pubchem ID :52988181
Synonyms :

Calculated chemistry of [ 1035219-96-5 ]

Physicochemical Properties

Num. heavy atoms : 11
Num. arom. heavy atoms : 5
Fraction Csp3 : 0.33
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 49.58
TPSA : 70.23 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.54 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.53
Log Po/w (XLOGP3) : 1.66
Log Po/w (WLOGP) : 0.81
Log Po/w (MLOGP) : 0.4
Log Po/w (SILICOS-IT) : 3.01
Consensus Log Po/w : 1.48

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.67
Solubility : 0.501 mg/ml ; 0.00215 mol/l
Class : Soluble
Log S (Ali) : -2.75
Solubility : 0.416 mg/ml ; 0.00178 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.92
Solubility : 0.278 mg/ml ; 0.00119 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.6

Safety of [ 1035219-96-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1035219-96-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1035219-96-5 ]
  • Downstream synthetic route of [ 1035219-96-5 ]

[ 1035219-96-5 ] Synthesis Path-Upstream   1~5

  • 1
  • [ 26493-11-8 ]
  • [ 1035219-96-5 ]
YieldReaction ConditionsOperation in experiment
55% With copper(ll) bromide; isopentyl nitrite In acetonitrile at 20℃; for 1.5 h; A mixture of intermediate 3 (8 g, 39.8 mmol), copper (II) bromide (10.43 g, 46.68 mmol) and 3-methyl-l-nitrosooxy-butane (6.8 g, 58.35 mmol) in ACN (100 mL) was stirred at room temperature for 1.5 hours. The solvent was evaporated in vacuo. The residue thus obtained was dissolved in AcOEt and washed with H20. The organic layer was separated, dried (Na2S04), filtered and the solvents evaporated in vacuo to yield 5 g (55percent) of intermediate 4 that was used in the next step without further purification.
36% With copper(ll) bromide In tetrahydrofuran at 20℃; for 12 h; Step ii: 2-bromo-6,7-dihydrothiazolo[5,4-clpyridin-4(5H)-one
To a 50 mL round bottom flask, were added 2-amino-6,7-dihydrothiazolo[5,4-c]pyridin-4(5H)- one (0.4 g, 0.0023 mol) and THF (10 mL). To the same flask, amyl nitrite (1.6 mL) and copper (II) bromide (0.4 g) were added. The reaction mixture was stirred at RT for 12 h. The reaction mixture was diluted with ethyl acetate and washed with water. The organic layer was separated, washed with brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to get crude product. The crude product was purified by column chromatography using 60-120 silica gel and 50 percent ethyl acetate in hexane to get the title compound [0.2 g, 36 percent]. LC-MS: 232.0 [M+H]+.
Reference: [1] Patent: WO2011/73339, 2011, A1, . Location in patent: Page/Page column 43
[2] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 14, p. 4037 - 4043
[3] Patent: WO2015/101928, 2015, A1, . Location in patent: Page/Page column 66; 67
  • 2
  • [ 1312412-89-7 ]
  • [ 1035219-96-5 ]
YieldReaction ConditionsOperation in experiment
55% With copper(ll) bromide; isopentyl nitrite In acetonitrile at 20℃; for 1.5 h; A mixture of intermediate 4 (8 g, 39.8 mmol), copper (II) bromide (10.43 g, 46.68 mmol) and 3-methyl-l-nitrosooxy-butane (6.8 g, 58.35 mmol) in ACN (100 mL) was stirred at room temperature for 1.5 hours. The solvent was evaporated in vacuo. The residue thus obtained was dissolved in AcOEt and washed with H20. The organic layer was separated, dried (Na2S04), filtered and the solvent evaporated in vacuo to yield 5 g (55percent) of intermediate 6 that was used in the next step without further purification.
Reference: [1] Patent: WO2011/73347, 2011, A1, . Location in patent: Page/Page column 34
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 18, p. 7243 - 7259
[3] Patent: US2012/252800, 2012, A1, . Location in patent: Page/Page column 15
  • 3
  • [ 845267-78-9 ]
  • [ 1035219-96-5 ]
Reference: [1] Patent: WO2011/73339, 2011, A1,
[2] Patent: WO2011/73347, 2011, A1,
[3] Patent: US2012/252800, 2012, A1,
[4] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 14, p. 4037 - 4043
[5] Patent: WO2015/101928, 2015, A1,
  • 4
  • [ 1312412-87-5 ]
  • [ 1035219-96-5 ]
Reference: [1] Patent: WO2011/73339, 2011, A1,
[2] Patent: WO2011/73347, 2011, A1,
[3] Patent: US2012/252800, 2012, A1,
[4] Bioorganic and Medicinal Chemistry Letters, 2013, vol. 23, # 14, p. 4037 - 4043
[5] Patent: WO2015/101928, 2015, A1,
  • 5
  • [ 1312412-88-6 ]
  • [ 1035219-96-5 ]
Reference: [1] Patent: WO2011/73339, 2011, A1,
[2] Patent: WO2011/73347, 2011, A1,
[3] Patent: US2012/252800, 2012, A1,
[4] Patent: WO2015/101928, 2015, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1035219-96-5 ]

Bromides

Chemical Structure| 949922-52-5

[ 949922-52-5 ]

2-Bromo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine hydrochloride

Similarity: 0.85

Chemical Structure| 143150-92-9

[ 143150-92-9 ]

2-Bromo-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine

Similarity: 0.83

Chemical Structure| 365996-06-1

[ 365996-06-1 ]

tert-Butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

Similarity: 0.72

Chemical Structure| 1093106-54-7

[ 1093106-54-7 ]

1-(2-Bromo-4-methylthiazol-5-yl)ethanone

Similarity: 0.71

Chemical Structure| 496062-16-9

[ 496062-16-9 ]

2-Bromo-4-(2-hydroxyethyl)-5-methylthiazole

Similarity: 0.68

Amides

Chemical Structure| 26493-11-8

[ 26493-11-8 ]

2-Amino-6,7-dihydrothiazolo[5,4-c]pyridin-4(5H)-one

Similarity: 0.80

Chemical Structure| 365996-06-1

[ 365996-06-1 ]

tert-Butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

Similarity: 0.72

Chemical Structure| 848499-31-0

[ 848499-31-0 ]

2-Bromo-thiazole-5-carboxamide

Similarity: 0.67

Chemical Structure| 1251009-79-6

[ 1251009-79-6 ]

tert-Butyl (2-bromo-4,5,6,7-tetrahydrobenzo[d]thiazol-6-yl)carbamate

Similarity: 0.63

Chemical Structure| 1253654-37-3

[ 1253654-37-3 ]

tert-Butyl 2-bromo-6,7-dihydrothiazolo[4,5-c]pyridine-5(4H)-carboxylate

Similarity: 0.60

Related Parent Nucleus of
[ 1035219-96-5 ]

Other Aromatic Heterocycles

Chemical Structure| 949922-52-5

[ 949922-52-5 ]

2-Bromo-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine hydrochloride

Similarity: 0.85

Chemical Structure| 143150-92-9

[ 143150-92-9 ]

2-Bromo-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine

Similarity: 0.83

Chemical Structure| 26493-11-8

[ 26493-11-8 ]

2-Amino-6,7-dihydrothiazolo[5,4-c]pyridin-4(5H)-one

Similarity: 0.80

Chemical Structure| 365996-06-1

[ 365996-06-1 ]

tert-Butyl 2-bromo-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate

Similarity: 0.72

Chemical Structure| 259809-24-0

[ 259809-24-0 ]

5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine

Similarity: 0.72